GSK PLC SP. ADR/2 NEW (GS70) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GSK PLC SP. ADR/2 NEW (GS70) has a cash flow conversion efficiency ratio of 0.065x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€1.14 Billion ≈ $1.33 Billion USD) by net assets (€17.42 Billion ≈ $20.37 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GSK PLC SP. ADR/2 NEW - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how GSK PLC SP. ADR/2 NEW's cash flow conversion efficiency has evolved over time, based on yearly financial data. See GSK PLC SP. ADR/2 NEW (GS70) net assets for net asset value and shareholders' equity analysis.
GSK PLC SP. ADR/2 NEW Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GSK PLC SP. ADR/2 NEW ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
UBS Group AG
SW:UBSG
|
-0.043x |
|
Sanofi
MX:SNYN
|
0.023x |
|
China Life Insurance Co Ltd A
SHG:601628
|
0.225x |
|
BNP Paribas SA
PA:BNP
|
0.004x |
|
Trane Technologies plc
NYSE:TT
|
0.136x |
|
CME Group Inc
NASDAQ:CME
|
0.047x |
|
Eoptolink Technology Inc Ltd
SHE:300502
|
0.180x |
|
Air Liquide SA
PA:AI
|
0.130x |
Annual Cash Flow Conversion Efficiency for GSK PLC SP. ADR/2 NEW (2021–2025)
The table below shows the annual cash flow conversion efficiency of GSK PLC SP. ADR/2 NEW from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see GSK PLC SP. ADR/2 NEW (GS70) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €15.96 Billion ≈ $18.65 Billion |
€7.74 Billion ≈ $9.05 Billion |
0.485x | -3.13% |
| 2024-12-31 | €13.09 Billion ≈ $15.30 Billion |
€6.55 Billion ≈ $7.66 Billion |
0.501x | -5.32% |
| 2023-12-31 | €12.79 Billion ≈ $14.96 Billion |
€6.77 Billion ≈ $7.91 Billion |
0.529x | -27.86% |
| 2022-12-31 | €10.10 Billion ≈ $11.80 Billion |
€7.40 Billion ≈ $8.65 Billion |
0.733x | +96.80% |
| 2021-12-31 | €21.34 Billion ≈ $24.95 Billion |
€7.95 Billion ≈ $9.30 Billion |
0.373x | -- |
About GSK PLC SP. ADR/2 NEW
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more